Justus Duyster
Principal Investigator
Department of Hematology, Oncology and Stem-Cell Transplantation
Medical Center University of Freiburg
Hugstetter Straße 55
79106 Freiburg
- +49 761 270-34060
- justus.duyster@uniklinik-freiburg.de
- Homepage
Current position
Academic training
| 1982 – 1989 | Medical School, University of Freiburg |
Advanced academic qualifications
| 2002 | Habilitation in Medicine, Oncogenic kinases, TU München |
| 1987 – 1990 | Doctorate, Department of Cardiology, Albert-Ludwigs-Universität Freiburg |
Postgraduate positions
| Since 2013 | Medical Director, Comprehensive Cancer Center Freiburg (CCCF), Freiburg |
| Since 2012 | Head of Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center University of Freiburg |
| 2005 - 2012 | C3 Professor, Department Medicine III, TU München |
| 2003 | Deputy Clinical Director, Department Medicine III, TU München |
| 2002 | Consultant, Department Medicine III, TU München |
| 1998 | Physician (Fellow), Department Medicine III, TU München |
| 1996 - 1998 | Physician (Internal Resident), University Hospital Ulm |
| 1994 - 1996 | Physician (Internal Resident), Charite Berlin Hospital at the Max-Delbrück Centrum |
| 1992 - 1994 | Research Associate, Department of Biology, UCSD San Diego, USA |
| 1991 - 1992 | Research Associate, Biochemical Institute, Medical Center University of Freiburg |
| 1989 - 1991 | Internal Resident, Medical Center University of Freiburg |
Miscellaneous (Honors, Awards)
| 2000, 2001, 2007 | Best Abstract DGHO |
| 2003 | Prize of the German Cancer Society |
| 2001 | Young Investigator Award DGHO |
| 1996 | Franziska Kolb Prize for leukemia research |
| 1992 | Postdoc grant from the German Cancer Aid for two years |
Publications listed in PubMed®
Publications (based on CRC1479 funding)
Langenbach M, Giesler S, Richtsfeld S, da Costa-Pereira S, Rindlisbacher L, Wertheimer T, Braun LM, Andrieux G, Duquesne S, Pfeifer D, Woessner NM, Menssen HD, Taromi S, Duyster J, Boerries M, Brummer T, Blazar BR, Minguet S, Turko P, Levesque MP, Becher B, Zeiser R. MDM2 inhibition enhances immune checkpoint inhibitor efficacy by increasing IL-15 and MHC class II production. Mol Cancer Res. 2023 Apr 18:MCR-22-0898. doi: 10.1158/1541-7786.MCR-22-0898. Epub ahead of print.
Rückert T, Andrieux G, Boerries M, Hanke-Müller K, Woessner NM, Doetsch S, Schell C, Aumann K, Kolter J, Schmitt-Graeff A, Schiff M, Braun LM, Haring E, Kissel S, Siranosian BA, Bhatt AS, Nordkild P, Wehkamp J, Jensen BAH, Minguet S, Duyster J, Zeiser R, Köhler N. Human β-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling. Sci Transl Med. 2022 Dec 21;14(676):eabp9675. doi: 10.1126/scitranslmed.abp9675. Epub 2022 Dec 21. PMID: 36542690.
free full text: https://www.science.org/stoken/author-tokens/ST-951/full
Ho JNHG, Schmidt D, Lowinus T, Ryoo J, Dopfer EP, Gonzalo Núñez N, Costa-Pereira S, Toffalori C, Punta M, Fetsch V, Wertheimer T, Rittmann MC, Braun LM, Follo M, Briere C, Vinnakota JM, Langenbach M, Koppers F, Shoumariyeh K, Engel H, Rückert T, Märklin M, Holzmayer S, Illert AL, Magon F, Andrieux G, Duquesne S, Pfeifer D, Staniek J, Rizzi M, Miething C, Köhler N, Duyster J, Menssen HD, Boerries M, Buescher JM, Cabezas-Wallscheid N, Blazar BR, Apostolova P, Vago L, Pearce EL, Becher B, Zeiser R. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation. Blood. 2022 Sep 8;140(10):1167-1181. doi: 10.1182/blood.2022016082.
Highlighted by this Editorial: Bleakley M, Biernacki M. MDM2 inhibition augments GVL effect. Blood. 2022 Sep 8;140(10):1064-1065. doi: 10.1182/blood.2022017724. PMID: 36074535.
Haring E, Andrieux G, Uhl FM, Krausz M, Proietti M, Sauer B, Esser PR, Martin SF, Pfeifer D, Schmitt-Graeff A, Duyster J, Köhler N, Grimbacher B, Boerries M, Aumann K, Zeiser R, Apostolova P. Therapeutic targeting of endoplasmic reticulum stress in acute graft-versus-host disease. Haematologica. 2022 Jul 1;107(7):1538-1554. doi: 10.3324/haematol.2021.278387.
Kreutmair S, Lippert LJ, Klingeberg C, Albers-Leischner C, Yacob S, Shlyakhto V, Mueller T, Mueller-Rudorf A, Yu C, Gorantla SP, Miething C, Duyster J, Illert AL. NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis. Front Oncol. 2022 May 13;12:875117. doi: 10.3389/fonc.2022.875117.
El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S, Aumann K, Clarson J, Vinnakota JM, Shoumariyeh K, Miething C, Lopez AF, Brown MP, Duyster J, Hein L, Manz MG, Hughes TP, White DL, Yong ASM, Zeiser R. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun. 2021 Nov 8;12(1):6436. doi: 10.1038/s41467-021-26683-0.
Contact
